ProMIS publishes study showing PMN310's superior oligomer selectivity vs other Aβ antibodies

ProMIS Neurosciences Inc.

PMN310 displayed greatest selectivity for toxic soluble Aβ oligomers among tested antibodies.
PMN310 avoided binding to plaque and vascular deposits, potentially reducing ARIA-E and ARIA-H risks.
Weekly murine PMN310 dosing at 800 mg/kg for 26 weeks in AD mice showed no detectable brain hemorrhages.
Phase 1a study in healthy volunteers ongoing; initial safety/PK data expected mid-2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.